Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Holders of 5% or more of PCVX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Vaxcyte, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 10.10%13.1M shares | +0.70 ppfrom 9.40% | Feb 12, 20253 filings | Sep 8, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 10.10%13.1M shares | −1.30 ppfrom 11.40% | Feb 14, 20254 filings | Nov 14, 2025 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%13.0M shares | – | May 15, 20251 filing | May 15, 2025 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 8.60%11.3M shares | +2.20 ppfrom 6.40% | Nov 14, 20252 filings | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.60%9.83M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Vaxcyte, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20261:55 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 202610:28 AM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 8.60%11.3M shares | +2.20 ppfrom 6.40% | Dec 31, 2025 | SEC |
| Nov 14, 202512:18 PM ET | T. Rowe Price Investment Management, Inc. | 13G | 6.40%8.32M shares | New | Sep 30, 2025 | SEC |
| Nov 14, 202512:02 PM ET | Janus Henderson Group PLC | 13G/A | 10.10%13.1M shares | −1.30 ppfrom 11.40% | Sep 30, 2025 | SEC |
| Sep 8, 202511:46 AM ET | FMR LLCand 1 other | 13G/A | 10.10%13.1M shares | +0.70 ppfrom 9.40% | Aug 29, 2025 | SEC |
| Aug 14, 202511:00 AM ET | Janus Henderson Group PLC | 13G/A | 11.40%14.7M shares | +0.10 ppfrom 11.30% | Jun 30, 2025 | SEC |
| Aug 6, 202512:19 PM ET | FMR LLCand 1 other | 13G/A | 9.40%12.1M shares | −1.10 ppfrom 10.50% | Jun 30, 2025 | SEC |
| May 15, 20254:51 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%13.0M shares | – | Mar 31, 2025 | SEC |
| May 7, 202510:56 AM ET | Janus Henderson Group PLC | 13G/A | 11.30%14.5M shares | +2.80 ppfrom 8.50% | Apr 30, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.60%9.83M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 202512:12 PM ET | Janus Henderson Group PLC | 13G/A | 8.50%10.6M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:34 AM ET | FMR LLCand 1 other | 13G/A | 10.50%13.1M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Vaxcyte, Inc. shares.
No Form 144 notices for Vaxcyte, Inc. are on file.